A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Clinical trial NCT03708328 · COMPLETED

Trial details

NCT number: NCT03708328
Sponsor: Hoffmann-La Roche
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumors Metastatic Melanoma Non-small Cell Lung Cancer (NSCLC)Small Cell Lung Cancer (SCLC)Esophageal Squamous Cell Carcinoma (ESCC)

Start date: 2018-10-15
Primary completion: 2024-07-09
Enrollment: 134

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.